Given that the level of PSMA protein expression has been previously observed to associate with uptake and response to radiolabeled PSMA-targeting ligands both in vitro and in prostate cancer trials [25,26,27], we hypothesized that there exists a positive association between the RNA expression levels of PSMA and responses to radioligand interventions across tumor types. Here, FOLH1 is linked to prostate cancer.